Sera Prognostics, Inc. (NASDAQ:SERA) Shares Sold by Marquette Asset Management LLC

Marquette Asset Management LLC trimmed its position in Sera Prognostics, Inc. (NASDAQ:SERA) by 9.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 32,139 shares of the company’s stock after selling 3,548 shares during the quarter. Marquette Asset Management LLC owned about 0.10% of Sera Prognostics worth $192,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. CWM LLC acquired a new position in Sera Prognostics in the 4th quarter valued at about $242,000. Resource Consulting Group Inc. acquired a new position in shares of Sera Prognostics in the 4th quarter worth approximately $265,000. Vanderbilt University acquired a new position in shares of Sera Prognostics in the 4th quarter worth approximately $284,000. Finally, Perigon Wealth Management LLC acquired a new position in shares of Sera Prognostics in the 4th quarter worth approximately $509,000. 54.64% of the stock is currently owned by institutional investors and hedge funds.

Sera Prognostics Stock Performance

Shares of SERA stock traded up $0.41 during trading hours on Friday, hitting $10.75. The company had a trading volume of 59,111 shares, compared to its average volume of 138,989. The company’s fifty day moving average is $9.44 and its 200 day moving average is $6.21. Sera Prognostics, Inc. has a fifty-two week low of $1.52 and a fifty-two week high of $11.32.

Sera Prognostics (NASDAQ:SERA) last announced its earnings results on Wednesday, March 20th. The company reported ($0.25) earnings per share for the quarter, hitting the consensus estimate of ($0.25). Sera Prognostics had a negative net margin of 11,843.79% and a negative return on equity of 45.74%. The firm had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.10 million. As a group, equities research analysts predict that Sera Prognostics, Inc. will post -0.94 EPS for the current year.

Insider Buying and Selling

In other Sera Prognostics news, General Counsel Benjamin Jackson sold 5,665 shares of the stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $8.03, for a total value of $45,489.95. Following the sale, the general counsel now directly owns 152,035 shares of the company’s stock, valued at approximately $1,220,841.05. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, CEO Zhenya Lindgardt sold 27,997 shares of the stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $8.03, for a total value of $224,815.91. Following the transaction, the chief executive officer now directly owns 947,003 shares of the company’s stock, valued at approximately $7,604,434.09. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, General Counsel Benjamin Jackson sold 5,665 shares of the stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $8.03, for a total transaction of $45,489.95. Following the completion of the transaction, the general counsel now directly owns 152,035 shares in the company, valued at $1,220,841.05. The disclosure for this sale can be found here. Insiders have sold a total of 141,335 shares of company stock valued at $1,255,192 in the last ninety days. Company insiders own 15.60% of the company’s stock.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.